Covalon Announces Conference Call to Discuss First Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will
be releasing its Fiscal 2019 First Quarter financial results on Tuesday February 26th, 2019, after markets close. A
conference call to discuss the financial results will be held Wednesday February 27th, 2019, at 9:00am EST. To
participate in the conference call, please dial:
Toll-Free: 833.299.8117
International: 647.689.4535
Conference ID Code: 9088509
A recording of the call will be available by calling 855.859.2056 or 404.537.3406 and entering the conference ID code 9088509
from February 27th, 2019, at 12:00pm EST to March 6th, 2019, at 11:59pm EST.
Copies of Covalon’s financial statements and MD&A can be obtained on SEDAR at
www.sedar.com, as well as the Investor Relations tab of the Company’s website at
www.covalon.com.
About Covalon
Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the
world. Covalon's patented technologies, products, and services address the advanced healthcare needs of medical device companies,
healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions
in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device
coatings. To learn more about Covalon, visit our website at
www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate",
"plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or
be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of
integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements
whether as a result of new information, further events or otherwise.
Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site:
www.covalon.com
Twitter: @covalon
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005987/en/